{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"24","value":"23.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Overall survival will be from first dose of study drug until failure or death from any cause.","dispersionType":"Full Range","groups":[{"description":"All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.\n\nRuxolitinib: Ruxolitinib 5 mg tablets, 4 per dose","id":"OG000","title":"Ruxolitinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}